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Dextran sulfate protected bFGF from heat and acid inactivation and from proteolytic degradation. The protective effect was stronger than that 
of hcparin which is known as a stabilizer of bFGF. Dextran ~ulfat¢ and bFGF formed a high molecular weight complex via ionic interaction when 
mixed together in aqueous olution. The complex was dissociated when the ionic strength was increased and the protective effect was completely 
abolished. Successive digestion of bFO F with Staphylococcus a reu# V8 protease and pepsin followed by affinity chromatography on an immobilized 
dextran sulfate column and reversed-phase high performance liquid chromatography yielded three positively charged fragment peptides, Tyr a- 
Phe ~°. Tyrm~-TrpU~ and Tyrt-'a-Leu ~.  These results uggest that dextran sulfate stabilizes bFGF by binding close to the putative heparin binding 
sites of the bFGF molecule. 
Basic flbroblast growth factor; Dextran sulfate; Complex formation 
1, INTRODUCTION 
Basic fibroblast growth factor (bFGF) belongs to a 
group of growth factors that have mitogenic, neurotro- 
phie and angiogenic activities [1-3]. Because .~f its high 
affinity for heparin, bFGF is referred to as one of the 
heparin binding growth factors. Heparin protects 
bFGF from heat and acid inactivation [4]. It also pro- 
tects bFGF from degradation by trypsin and chymo- 
trypsin [5]. 
£. coil.derived recombinant bFGF and its genetically 
engineered acid-stable mutein CS23 (rbFGF-CS23) [6] 
have been demonstrated to significantly accelerate the 
healing of chronic duodenal ulcers produced by cys- 
teamine in rats [7]. Oral administration of rbFGF-CS23 
caused a significant increase in angiogenesis n the ulcer 
bed compared with that in untreated control rats [8]. 
These findings demonstrate the important role(s) of 
bFOF in the healing of duodenal ulcers and imply a 
novel pharmacological modulation of gastrointestinal 
ulcers. 
Since orally administered rbFGF-CS23 was found to 
be degraded by the digestive nzymes in the gastrointes- 
tinal tract, we examined the use of heparin-related rea- 
gents derived from natural and synthetic sources to pro- 
tect rbFGF-CS23 from proteolytie degradation. Of 
them, we found that dextran sulfate was most pot~at. 
We report here that dextran sulfate has high affinity for 
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bFGF and that it protects bFGF from heat, acid and 
proteolytie inactivation. 
2. MATERIALS AND METHODS 
2.1. Materia[~" 
Dextran sulfate with an average molecular weight of 7,500 was 
purchased from Seikagaku Kogyo Co. (Tokyo, Japan). Heparin was 
purchased from Roussel Uclaf (Paris, Fran~). Pepsin, TPCK-tmated 
trypsin and chymotrypsln 'were obtained from Sigma Chemical Co 
(MO, USA). $. aureus V8 protease was obtained from ICN immuno 
Biologicals (IL, USA). 
2.2. bFGF 
rbFGF-CS23 is a mutein of human bFQF derived from recombi- 
nant E. colt and in which Cys ~ and Cys a7 in the orisinai bFGF have 
both been replaced by serine residues [6]. The amount of molecules 
with an amino terminal Met was less than 0,1% in oar preparation. 
The amino acid residues are numbered starting from the amino-termi- 
nal Pro of the mature molecule in this paper, rbFGF..CS23 was puff- 
fled to homogeneity (99.8% pure as determined by d~asitomet~) and 
used throughout the work. 
2.3. Bioas#ay 
The proliferatlon-sdmulating activity of rbFGF.CS23 was deter- 
mined with fetal bovine heart endothelial (FBHE) cells ATCC CRL 
1395 by the 3-(4,5-dimgthylthiazol-2-yl)-2,5-diphenyltgtrazolium bro- 
mide (MTT) assay as described [9]. 
2.4. Dextran sulfate affinity chromatography 
rbFGF-CS23 (409 ,ug/ml) was incubated at 37'C for 16 h with S. 
aureta' V8 pratease at an F./$ ratio oi' 1:20 (w/w). The digest was 
applied to a dgxtran sulfate high performan~ liquid chromatogrdphy 
(HPLC) column (Shodex AF pak DS-894, 0.8 x 5 era, ghoko Co Ltd., 
Tokyo, Japan), and the fragment peptides were elated with a linear 
gradient of NaCl concentration from 0 to 2 M. The fra~qnent peptides 
having affinity for destran sulfate were pooled and digested further 
with pepsin at 37"C for 16 h. The peptic digest wa~ applied to the 
dextran sulfate HPLC column, and the peptides were eluted as de- 
scribed above. The fragment peptides thus obtained were pooled and 
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Fig, 1. Inactivation of rbFGF-CS23 by pepsin, trypsin and chymotrypsin  the presence o1' absence of dextran sulfate. (A) Time courses of 
inactivation, rbFGF.CS23 {200 pg/ml) was incubated at 37°C for 16 h with one-fiftieth) by weight, the amount of pepsin, trypsin or ehyinotrypsin 
in the presence (O) or absence (O) of an equimolar concentration fdextran sulfate, pH: 2,0 for pepsin and 7.4 for trypsin and chymotrypsin. (1) 
pepsin; (2) trypsin; and (3) ehymotrypsin, (B) RP-HPLC pattern of rbFGF-CS23 incubated with pepsin in the absence or presence ofde~tran sulfate, 
Aliquots of the 30 rain-reaction mixtures used for Fi 8. 1A~ were subjected to RP-HPLC using an Ultrapore RPSC column (0.46 × 7,5 era; Beckman 
Instruments lnc,, CA, USA), Elution was performed with a linear gradient of acetor~trile concentration i  the presence of 0,05% trifluoroaceti¢ 
acid. (l) incubat~ in the absence of dextran sulfate; and (2) in the presence of de×r.ran sulfate. The arrow indicates the rbFGF-C$23 peak, 
applied to a reversed-phase (RP) HPLC column (ODS 120T, 0,46 x 
25 cm, Tosoh, Tokyo. Japan). Elution was perlbrmed with a linear 
gradient of acetonitrile con~ntration i the presen¢~ of 0,05% tri- 
fluoroacetie acid. Peptide peaks were analyzed with a PICO TAG 
amino acid analyzer (Millipore, MA, USA) and gas phase protein 
sequencer 470A (Applied Biosystems Inc,, CA, USA), 
when used with rbFGF-CS23 at an equimolar  concen- 
tration under the experinaental condit ions. 
3.2. Pt'otection fJ'orn proteolytic degradation 
rbFGF-CS23 was treated with digestive enzymes 
3. RESULTS AND DISCUSSION 
3, I. Protection from heat and acid fnactivation 
Stabilizers for rbFGF-CS23 were screened from 
among heparin.related natural  and synthetic substances 
with respect o protect ion from acid and heat inactiva. 
t ie°. Of  them, dextran sulfate was found to be most  
potent, When rbFOF-CS23 was incubated at 37°C and 
at pEI 3.0, the biological activity was rapidly decreased 
with time and was almost completely abol ished after 2 
h. However,  in the presence o f  an equimolar concentra-  
tion o f  dextran sulfate, the biological activity was pro- 
tected, and 89% o f  the initial activity remained even 
after 2 h o f  incubat ion (Table 1). It  is worth not ing that 
heparin was much less effective than dextran sulfate 
244 
Table 1 
Residual activity of rbFGF-CS23 incubated at 37°C and at pH 3,0 in 
the presence of dextran sulfate or heparin 
Addition Incubation time (h) Residual activity (%) 
None 0 100 
2 l0 
20 2 
Dextran sulfate 2 89 
20 34 
Heparin 2 20 
20 4 
rbFGF-CS23 (100 ~trflml) was incubated at 37°C and at pH 3.0 for 
20 h with an equimolar concentration f dextran sulfate or heparin, 
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Fig. 2. GPC patterns of rbFGF-CS23 (A) and rbFGF-CS23-deztran sulfate complex (B). (A) rbFGF-CS23 (20/,tg) was subjected to GPC using 
a TSK gel 3000 SW column (0.75 × 60 cm; Tosoh). Elution was performed with 0.1 M phosphate buffer (pH 6.0) containing 0.1 M Na,,SO4 at a 
flow rate of 1.0 ml/min. (B) rbFGF-CS23 (100 #g/ml) was incubated with an equimolar concentration f dextran sudfam (46,ug,/ml) at room 
temperature for 30 rain. and an aliquot of the reaction mixture (20/~g as rbFGF-CS23) was subjected to GPC as described above. 
such as pepsin, trypsin and chymotrypsin the pres- 
ence or absence of dextran sulfate (Fig. IA). Samples 
were taken at the indicated times, and the remaining, 
activity was determined, rbFGF-CS23 lost its biological 
activity within 30 rain when incubated ,,vith pepsin at 
37°C and at pH 2.0 in the absence of dextran sulfate 
(Fig. IA~). The addition of an equimolar concentration 
of dextran sulfate protected rbFGF-CS23 from the in- 
activation by pepsin. About 50% of the initial activity 
remained after 2 h incubation, and about 15% of the 
initial activity was still detected even after 16 h. Consis- 
tently with the loss of biological activity, rbFGF-CS23 
was rapidly degraded by pepsin into fragment peptides 
in the absence of dextran sulfate as evidenced by the 
elution profile on a RP-HPLC column (Fig. IBm). The 
fragmentation was inhibited in the presence of dextran 
sulfate (Fig. I B:). Dextran sulfate also protected 
rbFGF-CS23 from inactivation by trypsin and chymo- 
trypsin (Fig. IA2 and A~). Sommer and Rifkin reported 
that complete protection of bFGF from tryptic dices. 
tion was achieved when heparin and bFGF were mixed 
in a molar ratio of 10:1 [5]. 
3.3. Comple.~: formation 
Dextran sulfate was mixed and incubated with 
rbFGF-CS23 in a molar ratio slightly in excess of 1:1, 
and the mixture was applied to a gel permeation chro- 
matography (GPC) column (TSK gel 3000SW, 0.75 x 
60 cm; Tosoh). The mixture gave a single but much 
broader peak having an apparent Me of about 45,000 
as compared with the sharp peak having a M~ of 17,000 
obtained for rbFGF-CS23 alone (Fig. 2), and the bio- 
logical activity coincided exactly with the peak. This 
indicates that rbFGF-CS23 and dextran sulfate formed 
a complex in the aqueous olution and that the biolog- 
ical activity migrated with the complez. The broader 
peak of the complex may be a reflection of the broader 
size distribution of the dextran sulfate preparation used 
ill this study. 
The complex was dissociated into rbFGF-CS23 and 
dextran sulfate when NaCI was added at a concentra- 
tion higher than 0.75 M, and the activity peak on gel 
filtration shifted to a lower M~ (data not shown). The 
protective ffect of dextran sulfate at pH 3.0 and 370C 
on rbFGF-CS23 was completely abolished in the pres- 
ence of >0.75 M NaCI. These results indicate that the 
association of bFGF and dextran sulfate is due to ionic 
interactions and that the association is essential for the 
protection of the biological activity of bFGF. 
3.4. Bittding sites aa bFGF 
To study the binding site(s) on rbFGF-CS23 for dex- 
tran sulfate, rbFGF-CS23 was digested with $. aureus 
V8 protease, and the fragment peptides having affinity 
for dextran sulfate were obtained by affinity chroma- 
tography on an immobilized extran sulfate column 
(data not snows). The obtained fragments, Asp~-Glu 4s 
and $er~U°-Ser ~46. were pooled and subjected further to 
peptic digestion. The peptic digest was then applied to 
the same dextran sulfate column and peptides were 
eluted with a linear gradient of NaC! concentration 
from 0 to 2 M. The peptides having affinity for dextran 
sulfate thus obtained were pooled and subjected to RP- 
HPLC to give three positively charged fragment pep- 
tides (Fig. 3): Tyr~°~-Trp TM (peak l:Tyr-Arg-Ser-Arg- 
Lys-Tyr-Thr-Ser-Trp), Tyr~24.Leu138 (peak 2: Tyr-Lys- 
Leu-Gly-Ser-Lys-Thr-Gly-Pro-Gly-Gln-Lys-Ala-lle- 
Leu) and Tyr~4-Phe~° (peak 3: Tyr-Cys-Lys-Asn-Gly- 
Gly-Phc). 
Baird et al. reported several synthetic peptides~ FGF- 
(24--68)-NH2 and those containing residues 106-120 of 
bFGF, bind to heparin [10]. $eno et al. reported that 
deletion of the carboxyl-terminal 40-42 residues of 
bFGF greatly diminishes heparin affinity [! 1]. Consis- 
tently with their observations for heparin, our finding 
245 
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Fig. 3. RP-HPLC pattern of fragment pcptides derived from rbFGF. 
C523 having aflanity for dextran sulfate. A mixture of peptic frag. 
meats derived from rbFGF.CS23 which had been obtained by affinity 
chromatography ona dextran sulfate column was subjected to gP. 
HPLC as described inMaterials and Methods. Peaks (1) Tyf°~-TrpZ t4; 
(2) Tyrt"4-Leu~; and (3) Tyr:~-Ph~m.The peaks observed between 0 
and 5 rain are those derived from the solvent and the reagents. 
that Tyr'-4-Phe 3°, Tyr~°~-Trp tt4 and TyrL'~4-Leu ~3s bound 
to dextran sulfate indicates that the basic residues lo- 
cated in these peptides play an important role(s) in the 
binding of bFGF to dextran sulfate. Recently, based on 
three-dimensional structure analysis of  bFGF,  a cluster 
o f  several basic amino acid residues was found on the 
surface of the bF(3F molecule and suggested to consti- 
tute binding sites for heparin and other sulfated sub- 
strates [12-14]. Despite limitations of  our approach to 
identify the dextran sulfate-binding sites of bFGF,  it is 
worth noting that the four basic residues, Lys :~, Lys t2s, 
Lys L:9 and Lys ~3s, are included in our fragment peptides 
having affinity for dextran sulfate. Eriksson et ai. 
showed that four sulfate oxygens of  heparin are hydro- 
gen-bonded by the side chains of  Ash ~'7, Arg t2° and 
Lys t-~s as well as the main-chain amide of  Arg ~:° [12]. 
Asn -'7 and Lys ~'-~ are also included in our fragment pep- 
tides. 
In conclusion, our results presented in this paper sug- 
gest that dextran sulfate stabilizes bFGF by binding 
close to the putative heparin binding sites of  bFGF. The 
effect of  orally administering dextran sulfate together 
with bFGF on the acceleration of  the healing ofehronie 
duodenal ulcers in rats remains to be elucidated, 
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